TICKERNERD
Menu
APYXAPYXHealthcare · Medical Devices

APYX Stock Forecast: Apyx Medical Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.11
+2.48% on the day

The 5 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +93.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$131.4M
Ticker Nerd rank
70 / 100
Median analyst target
$6.00
Analysts covering
5
Total return, dividends reinvested
1W
+2.5%
1M
−24.6%
YTD
−11.3%
1Y
+50.7%
From 52W high
−36.1%
From 52W low
+63.4%
$1.90
$4.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APYX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Momentum
83
Quality
73
Size
73
Revisions
58
Value
53
Volatility
49
Issuance
27
Accruals
26

Growth (86): Sales and profits are climbing, and climbing faster than before.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Oct 25Jan 26Apr 26Jul 26APYXHigh $8.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $6.00Median $6.00High $8.00

The green dot is the last close — the median target sits +93.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026HC Wainwright & Co.InitiatesBuy$7.00
11 Mar 2026BTIGUpgradeBuy—
11 Mar 2026Craig-HallumMaintainsBuy—
16 Dec 2025Roth CapitalInitiatesBuy—
12 Nov 2025CitizensUpgradeMarket Outperform—
17 Oct 2024BTIGInitiatesNeutral—
16 Sept 2024JMP SecuritiesReiteratesMarket Perform—
10 Nov 2023Stephens & Co.MaintainsOverweight—
11 Aug 2023Piper SandlerMaintainsOverweight—
14 July 2023Stephens & Co.InitiatesOverweight—
15 June 2023Lake StreetMaintainsBuy—
24 May 2023JMP SecuritiesReiteratesMarket Perform—
12 May 2023Lake StreetMaintainsBuy—
8 Dec 2022Lake StreetAssumesBuy$5.00
12 Aug 2022Piper SandlerMaintainsOverweight—
19 July 2022Lake StreetMaintainsBuy—
20 May 2022Lake StreetInitiatesBuy—
13 Aug 2021JMP SecuritiesMaintainsMarket Outperform—
12 May 2020JMP SecuritiesMaintainsMarket Outperform—
12 Nov 2019Piper JaffrayMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APYX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

APYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Apyx Medical Corp. (APYX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.5×

Cheaper than 93% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
12.3×

Cheaper than 9% of US stocks

EV / EBITDA
−52.2×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
22.1%

Higher than 72% of US stocks

Earnings growth (YoY)
22.1%

Higher than 61% of US stocks

Gross margin
63.9%

Higher than 77% of US stocks

Operating margin
−13.0%

Higher than 23% of US stocks

Net margin
−14.8%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−90.7%

Higher than 14% of US stocks

Return on assets
−3.7%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

APYX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
APYXApyx Medical Corp.$131.4M
70
QTRXQuanterix Corp.$140.8M
28
MXCTMaxCyte, Inc.$147.8M
72
OWLTOwlet, Inc.$150.8M
34
INGNInogen, Inc.$152.8M
86
LNSRLENSAR, Inc.$103.6M
60
MBOTMicrobot Medical, Inc.$100.7M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APYX news & analysis

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

MarketBeat · 12 Aug 2026positive

Apyx Medical is positioning its Renuvion technology and newly launched AYON Body Contouring System to serve growing demand for surgical aesthetic procedures. CEO Charlie Goodwin said this demand has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Why it matters — Apyx watchers would care because the company is framing its aesthetic-device lineup as a beneficiary of the GLP-1 weight-loss trend driving demand for body-contouring procedures.

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Apyx Medical Corporation (APYX). The transcript covers the company's second-quarter 2026 earnings discussion with investors.

Why it matters — APYX watchers can review management's own commentary on the company's Q2 2026 results directly from the earnings call.

Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

Apyx Medical reported a Q2 loss of $0.07 per share, which came in wider than the Zacks Consensus Estimate of a $0.06 loss, though narrower than the $0.09 per-share loss a year earlier. The company beat revenue estimates for the quarter.

Why it matters — For APYX watchers, the quarter shows the company's bottom-line loss improved year over year while still coming in slightly worse than analyst expectations, offering a read on its earnings trajectory.

Apyx Medical Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Apyx Medical reported second-quarter revenue growth of 22% on its quarterly earnings call. The increase was driven by its surgical aesthetics business, boosted by adoption of the AYON Body Contouring System, international generator sales, and domestic demand for single-use handpieces.

Why it matters — APYX watchers would note the 22% revenue growth and the drivers cited for the company's recent performance.

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 6 Aug 2026neutral

Apyx Medical Corporation (NASDAQ:APYX), which markets Renuvion and the AYON Body Contouring System, reported its financial results for the second quarter ended June 30, 2026. The results were announced on August 6, 2026.

Why it matters — APYX watchers will want to track this quarterly financial report as it provides the latest update on the company's performance.

FAQ

Frequently asked questions about APYX stock

What is the APYX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APYX stock a buy right now?

Of the 5 analysts covering Apyx Medical Corp., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 70 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APYX?

As at 22 Aug 2026, Apyx Medical Corp. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will APYX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +93.2% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 70 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APYX stock forecast for 2030?

No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.

How has APYX stock performed over the past year?

Apyx Medical Corp. returned +50.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apyx Medical Corp. do?

Apyx Medical Corporation is an advanced energy technology company specializing in the design, development, and manufacturing of electrosurgical equipment and medical devices. The company is best known for its proprietary helium plasma technology, marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, which enables surgeons to precisely cut, coagulate, and ablate soft tissue during both open and minimally invasive procedures.

What is the latest news on APYX?

The most recent item we track (MarketBeat, 12 Aug 2026): "Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring". Apyx Medical is positioning its Renuvion technology and newly launched AYON Body Contouring System to serve growing demand for surgical aesthetic procedures. CEO Charlie Goodwin said this demand has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Company

About Apyx Medical Corp.

Apyx Medical Corporation is an advanced energy technology company specializing in the design, development, and manufacturing of electrosurgical equipment and medical devices. The company is best known for its proprietary helium plasma technology, marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, which enables surgeons to precisely cut, coagulate, and ablate soft tissue during both open and minimally invasive procedures. Apyx Medical also produces the AYON Body Contouring System, an all-in-one platform for body contouring that integrates advanced modalities for fat removal, tissue contraction, and aesthetic enhancement. In addition to its own branded products, the company leverages its expertise in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. Headquartered in Clearwater, Florida, Apyx Medical serves both domestic and international markets, supporting physicians and patients with innovative solutions that elevate surgical outcomes and patient care.

CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com